Discontinuation report CIPROFLOXACIN INJECTION
Report ID | 120710 |
Drug Identification Number | 02301296 |
Brand name | CIPROFLOXACIN INJECTION |
Common or Proper name | CIPROFLOXACIN INJECTION |
Company Name | BAXTER CORPORATION |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | CIPROFLOXACIN |
Strength(s) | 2MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS |
Packaging size | 100mL & 200mL |
ATC code | J01MA |
ATC description | QUINOLONE ANTIBACTERIALS |
Reason for discontinuation | Raw material availability |
Anticipated discontinuation date | 2020-07-31 |
Actual discontinuation date | 2020-07-31 |
Remaining supply date | 2020-07-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | This product was never marketed by Baxter Corporation. As such, there is no inventory of this product available. |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-07-21 | English | Compare |
v2 | 2020-07-21 | French | Compare |
v3 | 2020-07-21 | English | Compare |
v4 | 2020-07-21 | French | Compare |
v5 | 2020-08-17 | English | Compare |
v6 | 2020-08-17 | French | Compare |
Showing 1 to 6 of 6